top of page
Pipeline
MNC101-ALS
There is a high unmet need for effective therapies for degenerative diseases.
Current therapeutics are hindered by limited efficacy, severe toxicity, invasive and risky routes of administration, and elevated manufacturing costs. Currently, at the heart of our product development is MNC101, which aims to slow down and halt the progression of ALS, MS and diabetes.
Pipeline: MNC101
bottom of page